NeoGenomics (NEO) Tops Q4 EPS by 2c

NeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.05, $0.02 better than the analyst estimate of $0.03. Revenue for the quarter came in at $60.5 million versus the consensus estimate of $61.83 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Catalyst Metals Ltd (CYL:AU) PT Lowered to AUD9.25 at UBS
• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk